NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on.

Slides:

Advertisements

Similar presentations

TLX Homeodomain Oncogenes Mediate T Cell Maturation Arrest in T-ALL via Interaction with ETS1 and Suppression of TCRα Gene Expression Saïda Dadi, Sandrine.

Advertisements

Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia by Nathalie Dhédin, Anne Huynh, Sébastien.

Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? by Ching-Hon Pui, Charles G. Mullighan, William E. Evans, and Mary.

Maury S et al. Proc ASH 2015;Abstract 1.

Gamma Delta T Cell Reconstitution Is Associated with Fewer Infections and Improved Event-Free Survival after Hematopoietic Stem Cell Transplantation for.

Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura by Miguel Hie, Julie Gay, Lionel.

Secondary or Concomitant Neoplasms among Adults Diagnosed with Acute Lymphoblastic Leukemia (ALL) and Treated According to the LALA-87 and LALA-94 Trials.

A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia by Jean-Luc Harousseau,

Long-Term Follow-Up of the Imatinib GRAAPH-2003 Study in Newly Diagnosed Patients with De Novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia:

What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of.

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma.

The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma by Jonathan.

Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup by Jacques Delaunay, Norbert Vey, Thierry.

Building better therapy for children with acute lymphoblastic leukemia

Long-term follow-up of a randomized trial comparing the combination of cyclophosphamide with total body irradiation or busulfan as conditioning regimen.

Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup by Marie-Anne Hospital, Thomas Prebet,

Improved Treatment Results in Childhood B-Cell Neoplasms With Tailored Intensification of Therapy: A Report of the Berlin-Frankfurt-Münster Group Trial.

Long-term outcome after bone marrow transplantation for severe aplastic anemia by Lionel Ades, Jean-Yves Mary, Marie Robin, Christèle Ferry, Raphael Porcher,

Hypodiploidy With Less Than 45 Chromosomes Confers Adverse Risk in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Cancer Group by.

Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993.

Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value by Saman.

Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia by Yves Chalandon, Xavier.

Long-term outcome of higher-risk MDS patients treated with azacitidine: an update of the GFM compassionate program cohort by Raphael Itzykson, Sylvain.

Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism by Sabine Eichinger, Verena Schönauer, Ansgar Weltermann,

Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients by William J. Hogan,

Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system by.

Plasma thrombopoietin compared with immunoglobulin heavy-chain mutation status as a predictor of survival in chronic lymphocytic leukemia by Charles Koller,

Protease inhibitors potentiate chemotherapy-induced neutropenia

Nat. Rev. Urol. doi: /nrurol

Molecular Classifiers for Prediction of Minimal Residual Disease (MRD) and Event Free Survival (EFS) Improve Risk Assignment at Diagnosis in Pediatric.

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results by Lionel Adès, Miguel A. Sanz,

Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma by Weiyun Z. Ai, Robert Tibshirani, Behnaz.

Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia by Davide Rossi, Silvia Rasi, Valeria.

Randomized comparison of double induction and timed-sequential induction to a “3 + 7” induction in adults with AML: long-term analysis of the Acute Leukemia.

Granulocyte Colony-Stimulating Factor as an Adjunct to Induction Chemotherapy for Adult Acute Lymphoblastic Leukemia — A Randomized Phase-III Study by.

Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia by Sarah Bertoli,

FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with.

Jacob M. Rowe Biology of Blood and Marrow Transplantation

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

Practical Radiation Oncology

Randomized study of imatinib for chronic myeloid leukemia: comparing standard dose escalation with aggressive escalation by Koichi Miyamura, Kazunori Ohnishi,

Peripheral Blood Lymphocyte and Monocyte Recovery and Survival in Acute Leukemia Postmyeloablative Allogeneic Hematopoietic Stem Cell Transplant Mary.

Allogeneic Hematopoietic Cell Transplantation in Children with Relapsed Acute Lymphoblastic Leukemia Isolated to the Central Nervous System Paul D. Harker-Murray,

Kenneth Ouriel, MD, Daniel G. Clair, MD, K

(A) Kaplan-Meier curve showing AF-free survival after a single procedure for patients grouped according to use of CT integration. (A) Kaplan-Meier curve.

Allogeneic Bone Marrow Transplantation in First Remission for Children with Ultra-high- risk Features of Acute Lymphoblastic Leukemia: A Children’s Oncology.

Long-term results estimates for patients with anomalous origin of coronary artery from the pulmonary artery, showing survival, freedom from coronary and.

Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia by Thai Hoa Tran, Marian.

Nonmyeloablative Stem Cell Transplantation for Myelodysplastic Syndrome or Acute Myeloid Leukemia in Patients 60 Years or Older Vikas Gupta, Andrew Daly,

Donor Cell Leukemia: A Review

Kaplan-Meier-estimated PFS and OS are presented, with PFS in c-Met high and low patients shown in (A), OS in c-Met high and low patients in (B), PFS in.

Randomized trial comparing standard vs sequential high-dose chemotherapy for inducing early CR in adult AML by Renato Bassan, Tamara Intermesoli, Arianna.

The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Acute Lymphoblastic Leukemia in Adults: An Evidence-based.

Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.

Kaplan-Meier survival analysis for all-cause and CVD mortality in 2,823 type 2 diabetic patients stratified by CKD according to each creatinine-based equation.

Outcome of treatment in adults with Philadelphia chromosome–positive acute lymphoblastic leukemia—results of the prospective multicenter LALA-94 trial.

A, Overall survival of patients treated with CAR T cells (black line; n = 15). A, Overall survival of patients treated with CAR T cells (black line; n.

Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier plots. Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier.

Kaplan-Meier survival analysis of p53 mutation in the overall breast tumor series. Kaplan-Meier survival analysis of p53 mutation in the overall breast.

The influence of stem cell source on transplant outcomes for pediatric patients with acute myeloid leukemia by Amy K. Keating, Jurgen Langenhorst, John.

CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML by Claire M. Lucas, Laura J. Scott, Natasha Carmell,

by Jan J. Cornelissen, and Didier Blaise

Health-Related Quality of Life (HRQoL) of Blinatumomab Versus Standard of Care (SOC) Chemotherapy in Patients with Relaspsed or Refractory Philadelphia.

Evaluation of Salvage Induction Chemotherapy Regimens in Higher Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia after Hypomethylating Agent Treatment.

Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and.

How I treat T-cell acute lymphoblastic leukemia in adults

Cold agglutinin disease

Outcomes in patients with PTCL

Kaplan-Meier event-free survival from ipsilateral stroke for patients with near occlusion, pooled data from the NASCET and ECST. The 3-year intention-to-treat.

Presentation transcript:

NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study by Vahid Asnafi, Agnès Buzyn, Sandrine Le Noir, Frédéric Baleydier, Arnauld Simon, Kheira Beldjord, Oumedaly Reman, Francis Witz, Thierry Fagot, Emmanuelle Tavernier, Pascal Turlure, Thibaut Leguay, Françoise Huguet, Jean-Paul Vernant, Francis Daniel, Marie-Christine Béné, Norbert Ifrah, Xavier Thomas, Hervé Dombret, and Elizabeth Macintyre Blood Volume 113(17):3918-3924 April 23, 2009 ©2009 by American Society of Hematology

Kaplan-Meier estimates of event-free survival or overall survival according to NOTCH1 mutation. Kaplan-Meier estimates of event-free survival or overall survival according to NOTCH1 mutation. (A) Event-free survival (EFS); (B) overall survival (OS). Patients with ALL with a wild-type genotype of NOTCH1 (black line; n = 53) have a significantly higher risk of event or death than patients with ALL with mutated NOTCH1 (dashed line; n = 88). Vahid Asnafi et al. Blood 2009;113:3918-3924 ©2009 by American Society of Hematology

Kaplan-Meier estimates of event-free survival or overall survival according to NOTCH1 and/or FBXW7 mutations. Kaplan-Meier estimates of event-free survival or overall survival according to NOTCH1 and/or FBXW7 mutations. (A) Event-free survival (EFS); (B) overall survival (OS). Patients with ALL with a wild-type genotype of NOTCH1 and FBXW7 (black line; n = 40) have a significantly higher risk of event or death than patients with ALL with a mutated NOTCH1 and/or FBXW7 (dashed line; n = 110). Vahid Asnafi et al. Blood 2009;113:3918-3924 ©2009 by American Society of Hematology

Kaplan-Meier estimates of overall survival of patients with ALL according to the presence of a NOTCH1 and/or FBXW7 mutations and according to the chemotherapeutic protocol. Kaplan-Meier estimates of overall survival of patients with ALL according to the presence of a NOTCH1 and/or FBXW7 mutations and according to the chemotherapeutic protocol. Survival of patients with a wild-type genotype of NOTCH1 and FBXW7, treated with the LALA-94 protocol (n = 25); survival of patients with a wild-type genotype of NOTCH1 and FBXW7, treated with the GRAALL-2003 protocol (n = 15); patients with a mutated genotype of NOTCH1 and/or FBXW7, treated with the LALA-94 protocol (n = 62); patients with a mutated genotype of NOTCH1 and/or FBXW7, treated with the GRAALL-2003 protocol (n = 39). Vahid Asnafi et al. Blood 2009;113:3918-3924 ©2009 by American Society of Hematology